Big Sioux Wealth Management’s SAB Biotherapeutics SABS Stock Holding History
Bought
Maintained
Sold
Other funds holding SABS
Big Sioux Wealth Management's SABS Position: Q3 2026 in Review
Big Sioux Wealth Management sold out of SAB Biotherapeutics (SABS) in Q3 2026, closing a stake of 337 shares — an estimated $1.31K sold.
Big Sioux Wealth Management first reported a position in SABS in Q4 2025 and held it in 3 quarters. The position peaked at $1.31K in Q2 2026. 102 funds tracked by Wall St. Rank hold SABS as of Q3 2026.
- Big Sioux Wealth Management reported no remaining SAB Biotherapeutics position as of Q3 2026 after selling out during the quarter.
- Big Sioux Wealth Management sold 337 SAB Biotherapeutics shares in Q3 2026, an estimated $1.31K.
- Big Sioux Wealth Management first reported a position in SAB Biotherapeutics in Q4 2025 and held it in 3 quarters.
- Big Sioux Wealth Management's SAB Biotherapeutics position peaked at $1.31K in Q2 2026.
- 102 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q3 2026.
Based on Big Sioux Wealth Management's 13F filing for Q3 2026, filed 19 Nov 2026.